Company: CGC
Filing Date: 2025-05-30
Form Type: POS AM
Source: 0001104659-25-054925
Chunk: 84

Company: Canopy Growth Corp
Filing Date: 2025-05-30
Form: POS AM
Chunk 84
---
 Before making an investment decision, you should carefully consider the risk factors described under “Item 1A Risk Factors” in our most recent Annual Report on Form 10-K as updated by the risk factors described under “Item 1A Risk Factors” in our subsequently filed Quarterly Reports on Form 10-Q or in any other periodic reports and documents we file from time to time with the SEC, together with all of the other information appearing in or incorporated by reference into this prospectus, before deciding whether to purchase any of our Common Shares being offered. Our business, financial condition or results of operations could be materially adversely affected by any of these risks. The trading price of our Common Shares could decline due to any of these risks, and you may lose all or part of your investment. Please also read carefully the sections titled “Special Note Regarding Forward-Looking Statements; Risk Factor Summary” in our most recent Annual Report on Form 10-K.

<div align='center'>3</div>

TABLE OF CONTENTS

### THE COMPANY
We are a world-leading cannabis company which produces, distributes, and sells a diverse range of cannabis and cannabis-related products. Our cannabis products are principally sold for adult-use and medical purposes under a portfolio of distinct brands in Canada pursuant to the Cannabis Act , SC 2018, c 16, and globally pursuant to applicable international and Canadian legislation, regulations, and permits. Our core operations are in Canada, Germany and Australia.

The Company’s principal executive offices are located at 1 Hershey Drive, Smiths Falls, Ontario, K7A 0A8. Our Common Shares are listed for trading on the TSX under the symbol “WEED” and Nasdaq under the symbol “CGC.” The Company maintains a website at www.canopygrowth.com . The information on, or otherwise accessible through, our website does not constitute a part of, and is not incorporated by reference into, this prospectus.

<div align='center'>4</div>

TABLE OF CONTENTS

### USE OF PROCEEDS
We will receive no proceeds from the sale of the Shares by the Selling Securityholders. We would, however, receive proceeds upon the exercise of the September 2023 Warrants, the January 2024 Warrants, the May 2024 Warrants and the Put Warrants (collectively, the “Warrants”) held by certain of the Selling Securityholders which, if such Warrants are exercised in full for cash, would be approximately US$110.5 million (with respect to